Italy · Delayed Price · Currency is EUR Recordati Industria Chimica e Farmaceutica Earnings Call Transcripts
Fiscal Year 2026
-
Rare diseases drive high-teen growth and now represent 40% of 2025 revenue, with Isturisa’s U.S. label extension and Enjaymo’s integration fueling expansion. SPC remains stable, and disciplined R&D and BD support long-term targets despite FX and product headwinds.
Fiscal Year 2025
-
Revenue grew 11.8% to €2.62B in 2025, with rare disease up 29.7% and EBITDA margin at 37.8%. 2026 guidance targets €2.73–2.8B revenue and high-teens rare disease growth, despite FX headwinds. Investments in ISTURISA and new partnerships, including Moderna, support future growth.
-
Strong revenue and EBITDA growth were reported, with rare disease driving high teens growth and Isturisa’s peak sales guidance raised above €1.2 billion. Strategic investments and M&A continue, with 2026 marked as an investment year impacting margins, but long-term guidance and operational efficiency remain robust.
-
Revenue grew 12.2% to €1.96B with strong rare disease momentum and U.S. growth over 30%. Isturisa’s peak sales estimate doubled to €1.2B+, driving major investment for expanded patient reach. FX headwinds and Cardicor license loss will impact 2026, but long-term growth outlook remains robust.
-
Revenue grew 11.7% year-over-year to EUR 1.32 billion, with strong gains in rare diseases and specialty care. EBITDA margin was 37.5%, and full-year guidance was confirmed despite FX headwinds. Vascepa and Vistariza are expected to drive future growth.
-
Q1 2025 saw 11.9% revenue growth to €680M, with strong gains in both specialty/primary care and rare disease. EBITDA margin was 39.7%, and adjusted net income rose 7.2%. Full-year guidance and 2027 double-digit growth targets were reaffirmed.
-
Ambitious targets include doubling revenue by 2030 and achieving €3–3.2 billion revenue by 2027, driven by diversified growth in specialty care and rare diseases. Recent product approvals and disciplined M&A support strong financial performance and resilience.
-
Recordati projects strong growth in both specialty primary care and rare disease, with 2025 revenues expected to surpass EUR 2.6 billion and rare disease approaching 40% of total sales. Recent M&A, including the Enjaymo acquisition, is immediately accretive, and the company remains focused on disciplined expansion, high margins, and key product milestones in 2025.
Fiscal Year 2024
-
2024 saw double-digit revenue and profit growth, with rare diseases and specialty care both outperforming. 2025 guidance targets further margin expansion and strong top-line growth, supported by new product launches and increased peak sales targets for key assets.
-
The conference featured a rare disease pharma CEO discussing international growth, M&A, and innovation, while panels debated strategic options for biotech exits amid a buoyant 2025 market. Investor focus remains on management, science, and deal flexibility.
-
Revenue grew 12% year-over-year to €1,743 million, with strong performance in both specialty primary care and rare diseases. EBITDA margin reached 38.2%, and free cash flow was €434.3 million. Full-year guidance is confirmed, with minimal 2024 impact from the Enjaymo acquisition.
-
Acquisition of global rights to Enjaymo strengthens the rare disease and hematology portfolio, with strong IP protection, limited competition, and expected peak sales of EUR 250–300 million. The deal is financed mainly by new debt and is set to close by end-2024, pending regulatory approval.
-
H1 2024 saw net revenue rise 30.5% year-over-year to €1.185 billion, with strong growth in both specialty/primary care and rare disease. EBITDA margin remained above 38%, and full-year guidance was raised, reflecting robust momentum and sector-leading profitability.